The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
STARLITE 2: Phase 2 study of nivolumab plus 177lutetium-labeled anti–carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab (177Lu-girentuximab) in patients (pts) with advanced clear cell renal cell carcinoma (ccRCC).
 
Darren R. Feldman
Consulting or Advisory Role - Cigna
Research Funding - Astellas Pharma; Decibel Therapeutics (Inst); Seagen
Other Relationship - UpToDate
 
Robert J. Motzer
Consulting or Advisory Role - AstraZeneca; Aveo; Calithera Biosciences; Eisai; EMD Serono; Exelixis; Genentech/Roche; Incyte; Merck; Pfizer
Research Funding - Aveo (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Andrea Knezevic
Consulting or Advisory Role - ByHeart
 
Chung-Han Lee
Honoraria - American Institute of Continuing Medical Education; IDEOlogy Health; Intellisphere; Medscape; Research to Practice
Consulting or Advisory Role - AVEO; Bristol-Myers Squibb; Cardinal Health; Eisai; Eisai; Exelixis; Merck; Pfizer/EMD Serono
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Eisai (Inst); Exelixis (Inst); Merck (Inst)
 
Martin H Voss
Stock and Other Ownership Interests - CellGenix (I)
Consulting or Advisory Role - Affimed Therapeutics; AVEO; Calithera Biosciences; Eisai; Exelixis; Genentech; Merck; MicuRx Pharmaceuticals; Oncorena; OnQuality Pharmaceuticals
Research Funding - Pfizer
Other Relationship - BMS
(OPTIONAL) Uncompensated Relationships - Aravive; BMS; Genentech/Roche
 
Serge K. Lyashchenko
Leadership - Evergreen Theragnostics
Stock and Other Ownership Interests - Evergreen Theragnostics
Consulting or Advisory Role - Clarity Pharmaceuticals; Evergreen Theragnostics; YmAbs Therapeutics Inc
 
Hijin Park
Stock and Other Ownership Interests - Ymabs Therapeutics Inc
 
Steven M. Larson
Stock and Other Ownership Interests - Elucida Oncology; YmAbs Therapeutics Inc
Consulting or Advisory Role - Prescient Therapeutics
Research Funding - Wilex; YmAbs Therapeutics Inc
Patents, Royalties, Other Intellectual Property - Antigen-Specific Composition and In Vivo Methods for Detecting and Localizing an Antigenic Site and for Radiotherapy. Larson SM, Finn R, Carrasquillo JA, Reynolds JC, Neumann RD, Graham MC, Pentlow KS. U.S. Patent No. 5,185,142. Date: Feb. 9, 1993.; Multi-Specific Antibodies with Affinity for Human A33 Antigen and DOTA Metal Complex and Uses Thereof . Cheal S, Hong Xu, Larson SM, NK Cheung. US Patent No. 62,113,988. Date 2/09/2015.; Non-invasive imaging and Quantification of Specific Antigen and Uses Thereof. Smith-Jones, P and Larson SM. Provisional Patent Application. Registration Number 28,325. Date 1/06/03.; Single chain Fv polynucleotide or peptide construct of anti-ganglioside GD2 antibodies, cells expressing same and related methods NK Cheung, SM Larson, HF Guo, K Rivlin, M. Sadelain US Patent No. 6,451,995.; Small-Molecule HSP90 Inhibitors, Chiosis, Gabriela; Huazhong He, Llauger-Bufi, Laura; Kim Joungnam; Larson, Steve; Smith-Jones, Peter. US Patent No. 7,834,181. Date 11/16/10.; Synthesis and Utilization of 17-methyl and 17-cyclo-propylmethyl-3, 14-Di-hydroxy-4, 5-Epoxy 6 b-Fluoromorphines (Foxy and cyclofoxy) as (18F)-labeled opiate ligands for positron emission transaxial tomography. (PET) Rice KC, Pert CB, Burke TR, Jr., Larso; Systems and Methods for Determining Optimum Patient-Specific Antibody Dose for Tumor Targeting. Zanzonico P, Cheal SM, Larson SM, Osborne J, Fung Edward K. US Patent No. 62,165699. Date 5/22/2015
 
Neeta Pandit-Taskar
Honoraria - Actinium Pharmaceuticals
Consulting or Advisory Role - Actinium Pharmaceuticals; Fusion Pharmaceuticals; Illumina; progenics
Speakers' Bureau - Actinium Pharmaceuticals
Research Funding - Bayer Health (Inst); Bristol-Myers Squibb (Inst); Clarity Pharmaceuticals (Inst); Fusion Pharmaceuticals (Inst); Imaginab (Inst); Janssen (Inst); Regeneron (Inst)
Travel, Accommodations, Expenses - Bayer